Market closed
Regulus Therapeutics Inc./$RGLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Ticker
$RGLS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
34
Website
RGLS Metrics
BasicAdvanced
$119M
-
-$0.82
1.41
-
Price and volume
Market cap
$119M
Beta
1.41
52-week high
$2.05
52-week low
$1.22
Financial strength
Current ratio
10.981
Quick ratio
10.105
Long term debt to equity
0.359
Total debt to equity
1.381
Interest coverage (TTM)
-316.71%
Management effectiveness
Return on assets (TTM)
-54.42%
Return on equity (TTM)
-95.00%
Valuation
Price to book
1.54
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-2.414
Growth
Earnings per share change (TTM)
-48.07%
3-year earnings per share growth (CAGR)
-36.71%
RGLS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Regulus Therapeutics Inc. stock?
Regulus Therapeutics Inc. (RGLS) has a market cap of $119M as of April 05, 2025.
What is the P/E ratio for Regulus Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Regulus Therapeutics Inc. (RGLS) stock is 0 as of April 05, 2025.
Does Regulus Therapeutics Inc. stock pay dividends?
No, Regulus Therapeutics Inc. (RGLS) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Regulus Therapeutics Inc. dividend payment date?
Regulus Therapeutics Inc. (RGLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Regulus Therapeutics Inc.?
Regulus Therapeutics Inc. (RGLS) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.